Clinical results of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in children with advanced stage rhabdomyosarcoma

Nam Kyun Kim, Hyo Sun Kim, Chang Ok Suh, Hyun Ok Kim, Chuhl Joo Lyu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Regardless of improvement in cure of Rhabdomyosarcoma (RMS), the results in treatment of advanced stage of RMS in children are still dismal. Recently, high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/APBSCT) has been tried to manage the advanced high-risk RMS patients. We investigated the effectiveness of HDC/APBSCT by reviewing the clinical records of high-risk pediatric RMS patients in single institute database. Over twenty years, 37 patients were diagnosed as RMS with high-risk at the time of first diagnosis. These patients were classified as two groups according to treatment method. The first group was HDC/APBSCT and the other was conventional multi-agent chemotherapy group. Differences of clinical results between the two groups were analyzed. The median age of patients was 5 yr, ranging from 6 months to 15 yr. The 5-yr event free survival rate (EFS) of all patients was 24.8% ± 4.8%. HDC/APBSCT group and conventional multi-agent chemotherapy group were 41.3% ± 17.8% and 16.7% ± 7.6% for 5-yr EFS, respectively (P = 0.023). There was a significant difference in the result of HDC/APBSCT between complete remission or very good partial response group and poor response group (50% ± 20.4% vs 37.5% ± 28.6%, P = 0.018). HDC/APBSCT can be a promising treatment modality in high-risk RMS patients.

Original languageEnglish
Pages (from-to)1066-1072
Number of pages7
JournalJournal of Korean medical science
Volume27
Issue number9
DOIs
Publication statusPublished - 2012 Sep 1

Fingerprint

Peripheral Blood Stem Cell Transplantation
Rhabdomyosarcoma
Drug Therapy
Disease-Free Survival
Survival Rate
Therapeutics
Databases
Pediatrics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{cf3fc04615254c47bf2b1853ce0767a5,
title = "Clinical results of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in children with advanced stage rhabdomyosarcoma",
abstract = "Regardless of improvement in cure of Rhabdomyosarcoma (RMS), the results in treatment of advanced stage of RMS in children are still dismal. Recently, high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/APBSCT) has been tried to manage the advanced high-risk RMS patients. We investigated the effectiveness of HDC/APBSCT by reviewing the clinical records of high-risk pediatric RMS patients in single institute database. Over twenty years, 37 patients were diagnosed as RMS with high-risk at the time of first diagnosis. These patients were classified as two groups according to treatment method. The first group was HDC/APBSCT and the other was conventional multi-agent chemotherapy group. Differences of clinical results between the two groups were analyzed. The median age of patients was 5 yr, ranging from 6 months to 15 yr. The 5-yr event free survival rate (EFS) of all patients was 24.8{\%} ± 4.8{\%}. HDC/APBSCT group and conventional multi-agent chemotherapy group were 41.3{\%} ± 17.8{\%} and 16.7{\%} ± 7.6{\%} for 5-yr EFS, respectively (P = 0.023). There was a significant difference in the result of HDC/APBSCT between complete remission or very good partial response group and poor response group (50{\%} ± 20.4{\%} vs 37.5{\%} ± 28.6{\%}, P = 0.018). HDC/APBSCT can be a promising treatment modality in high-risk RMS patients.",
author = "Kim, {Nam Kyun} and Kim, {Hyo Sun} and Suh, {Chang Ok} and Kim, {Hyun Ok} and Lyu, {Chuhl Joo}",
year = "2012",
month = "9",
day = "1",
doi = "10.3346/jkms.2012.27.9.1066",
language = "English",
volume = "27",
pages = "1066--1072",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "9",

}

Clinical results of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in children with advanced stage rhabdomyosarcoma. / Kim, Nam Kyun; Kim, Hyo Sun; Suh, Chang Ok; Kim, Hyun Ok; Lyu, Chuhl Joo.

In: Journal of Korean medical science, Vol. 27, No. 9, 01.09.2012, p. 1066-1072.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical results of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation in children with advanced stage rhabdomyosarcoma

AU - Kim, Nam Kyun

AU - Kim, Hyo Sun

AU - Suh, Chang Ok

AU - Kim, Hyun Ok

AU - Lyu, Chuhl Joo

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Regardless of improvement in cure of Rhabdomyosarcoma (RMS), the results in treatment of advanced stage of RMS in children are still dismal. Recently, high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/APBSCT) has been tried to manage the advanced high-risk RMS patients. We investigated the effectiveness of HDC/APBSCT by reviewing the clinical records of high-risk pediatric RMS patients in single institute database. Over twenty years, 37 patients were diagnosed as RMS with high-risk at the time of first diagnosis. These patients were classified as two groups according to treatment method. The first group was HDC/APBSCT and the other was conventional multi-agent chemotherapy group. Differences of clinical results between the two groups were analyzed. The median age of patients was 5 yr, ranging from 6 months to 15 yr. The 5-yr event free survival rate (EFS) of all patients was 24.8% ± 4.8%. HDC/APBSCT group and conventional multi-agent chemotherapy group were 41.3% ± 17.8% and 16.7% ± 7.6% for 5-yr EFS, respectively (P = 0.023). There was a significant difference in the result of HDC/APBSCT between complete remission or very good partial response group and poor response group (50% ± 20.4% vs 37.5% ± 28.6%, P = 0.018). HDC/APBSCT can be a promising treatment modality in high-risk RMS patients.

AB - Regardless of improvement in cure of Rhabdomyosarcoma (RMS), the results in treatment of advanced stage of RMS in children are still dismal. Recently, high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/APBSCT) has been tried to manage the advanced high-risk RMS patients. We investigated the effectiveness of HDC/APBSCT by reviewing the clinical records of high-risk pediatric RMS patients in single institute database. Over twenty years, 37 patients were diagnosed as RMS with high-risk at the time of first diagnosis. These patients were classified as two groups according to treatment method. The first group was HDC/APBSCT and the other was conventional multi-agent chemotherapy group. Differences of clinical results between the two groups were analyzed. The median age of patients was 5 yr, ranging from 6 months to 15 yr. The 5-yr event free survival rate (EFS) of all patients was 24.8% ± 4.8%. HDC/APBSCT group and conventional multi-agent chemotherapy group were 41.3% ± 17.8% and 16.7% ± 7.6% for 5-yr EFS, respectively (P = 0.023). There was a significant difference in the result of HDC/APBSCT between complete remission or very good partial response group and poor response group (50% ± 20.4% vs 37.5% ± 28.6%, P = 0.018). HDC/APBSCT can be a promising treatment modality in high-risk RMS patients.

UR - http://www.scopus.com/inward/record.url?scp=84866361820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866361820&partnerID=8YFLogxK

U2 - 10.3346/jkms.2012.27.9.1066

DO - 10.3346/jkms.2012.27.9.1066

M3 - Article

C2 - 22969254

AN - SCOPUS:84866361820

VL - 27

SP - 1066

EP - 1072

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 9

ER -